Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M

ELITE PHARMACEUTICALS INC /NV/

2026-Q3 EPS reported $0.02 revenue$108,122,052

Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.
Net income $18.6M for three months ended Dec 31, 2025.
Growth driven by lisdexamfetamine and naltrexone product launches after prior year comparable period.
Conference call Feb 18, 2026 at 11:30 AM EST; questions due by Feb 17 evening.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.